An internal standard for the quantification of 13,14-dihydro-15-keto PGE2
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

13,14-dihydro-15-keto Prostaglandin E2-d9

Item No. 19348

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(Z)-7-((1R,2R,3R)-3-hydroxy-5-oxo-2-(3-oxooctyl-5,5,6,6,7,7,8,8,8-d9)cyclopentyl)hept-5-enoic acid
CAS Number
2750534-81-5
Synonyms
  • 13,14-dihydro-15-keto PGE2-d9
  • 13,14-dihydro-oxo-PGE2-d9
  • PGEM-d9
Molecular Formula
C20H23D9O5
Formula Weight
361.5
Purity
≥99% deuterated forms (d1-d9)
Formulation
A 100 µg/ml solution in methyl acetate
Solubility(Learn about Variance in Solubility)
DMF: 50 mg/mlDMSO: 50 mg/mlEthanol: 50 mg/mlPBS (pH 7.2): 1 mg/ml
SMILES
O=C1[C@H](C/C=C\CCCC(O)=O)[C@@H](CCC(CC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=O)[C@H](O)C1
InChi Code
InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,16-17,19,23H,2-3,5-6,8-14H2,1H3,(H,24,25)/b7-4-/t16-,17-,19-/m1/s1/i1D3,2D2,3D2,6D2
InChi Key
CUJMXIQZWPZMNQ-QNUVVDNFSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    25 µg

    $128

    Add

    50 µg

    $241

    Add

    100 µg

    $454

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    13,14-dihydro-15-keto-Prostaglandin E2-d9 (13,14-dihydro-15-keto PGE2-d9) is intended for use as an internal standard for the quantification of 13,14-dihydro-15-keto PGE2 (Item No. 14650) by GC- or LC-MS. 13,14-dihydro-15-keto PGE2 is a metabolite of PGE2 (Item No. 14010) and the primary PGE2 metabolite in plasma.1,2 It is formed from PGE2 via a 15-keto PGE2 intermediate by 15-oxo-PG Δ13 reductase.2 Unlike PGE2, 13,14-dihydro-15-keto PGE2 does not bind effectively to the PGE2 receptors EP2 and EP4 expressed in CHO cells (Kis = 12 and 57 µM, respectively) or induce adenylate cyclase activity in the same cells (EC50s = >18 and >38 µM, respectively). Levels of 13,14-dihydro-15-keto PGE2 are increased in the plasma of women in the third trimester of pregnancy and in women during and immediately after labor and delivery.3 Levels of 13,14-dihydro-15-keto PGE2 levels are decreased in tumor tissue compared to adjacent non-cancerous tissue isolated from patients with non-small cell lung cancer (NSCLC).4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Hamberg, M., and Samuelsson, B. On the metabolism of prostaglandins E1 and E2 in man. The Journal of Biological Chemisty 246(22), 6713-6721 (1971).

    2. Nishigaki, N., Negishi, M., and Ichikawa, A. Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. Mol. Pharmacol. 50(4), 1031-1037 (1996).

    3. Husslein, P., and Sinzinger, H. Concentration of 13,14-dihydro-15-keto-prostaglandin E2 in the maternal peripheral plasma during labour of spontaneous onset. Br. J. Obstet. Gynaecol. 91(3), 228-231 (1984).

    4. Hughes, D., Otani, T., Yang, P., et al. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev. Res. (Phila.) 1(4), 241-249 (2008).